Effect of saccharomyces boulardii in treatment of pediatric functional abdominal pain

Comparison between the efficacy of saccharomyces boulardii and placebo on treatment of pediatric functional abdominal pain

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180822040850N1

Enrollment

104

Registered

2019-11-23

Start date

2018-08-27

Completion date

Unknown

Last updated

2019-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional Abdominal Pain. Functional intestinal disorder, unspecified

Interventions

Intervention 1: Intervention group: Administration of Saccharomyces Bullardi (two capsules daily containing 250 mg). Intervention 2: Control group: treatment with Placebo.

Eligibility

Sex/Gender

All

Age

5 Years to 15 Years

Inclusion criteria

Inclusion criteria: Children from 5 to 15 years old Have rome 3 criteria for functional abdominal pain Participants and parents have informed consent Paraclinical is normal

Exclusion criteria

Exclusion criteria: Children who have visceral abdominal pain Children have abnormal laboratory tests findings Children have abnormal abnormal abdominopelvic sonography findings Parents of children have not completed the informed consent form

Design outcomes

Primary

Measure	Time frame
Pain Severity. Timepoint: 3 weeks after beginning of study and intervention. Method of measurement: OUCHER questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Dehdashtizadeh

Ilam University of Medical Sciences

adehdashtyzade@gmail.com+98 84 3333 4500

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026